Cargando…

Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease

AIM: To observe gene polymorphisms of TPMT and NUDT15, and compare their predictive value for azathioprine (AZA)-induced leukopenia in inflammatory bowel disease (IBD). METHODS: This study enrolled 219 patients diagnosed with IBD in Xiangya Hospital, Central South University, Changsha, China from Fe...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hong-Hui, He, Ying, Wang, Hong-Xian, Liao, Cheng-Ling, Peng, Yu, Tao, Li-Jian, Zhang, Wei, Yang, Hui-Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829157/
https://www.ncbi.nlm.nih.gov/pubmed/29491687
http://dx.doi.org/10.3748/wjg.v24.i8.941
_version_ 1783302749479239680
author Wang, Hong-Hui
He, Ying
Wang, Hong-Xian
Liao, Cheng-Ling
Peng, Yu
Tao, Li-Jian
Zhang, Wei
Yang, Hui-Xiang
author_facet Wang, Hong-Hui
He, Ying
Wang, Hong-Xian
Liao, Cheng-Ling
Peng, Yu
Tao, Li-Jian
Zhang, Wei
Yang, Hui-Xiang
author_sort Wang, Hong-Hui
collection PubMed
description AIM: To observe gene polymorphisms of TPMT and NUDT15, and compare their predictive value for azathioprine (AZA)-induced leukopenia in inflammatory bowel disease (IBD). METHODS: This study enrolled 219 patients diagnosed with IBD in Xiangya Hospital, Central South University, Changsha, China from February 2016 to November 2017. Peripheral blood of all patients was collected to detect their genotypes of TPMT and NUDT15 by pyrosequencing at the Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Xiangya Hospital. Eighty patients were treated with AZA according to the disease condition. During the first month, patients who received AZA underwent routine blood tests and liver function tests once a week. The endpoint of the study was leukopenia induced by AZA. By analyzing patient characteristics, genotypes and leukopenia induced by drug use, we found the risk factors associated with AZA-induced leukopenia. RESULTS: There were 219 patients with IBD (160 men and 59 women), including 39 who were confirmed with ulcerative colitis (UC), 176 with Crohn’s disease (CD) and 4 with undetermined IBD (UIBD). There were 44 patients (20.1%) with mutant genotype of NUDT15 (C/T); among them, 16 received AZA, and 8 (50%) developed leukopenia. There were 175 patients (79.7%) with wild genotype of NUDT15 (C/C); among them, 64 received AZA, and 11 (17.2%) developed leukopenia. A significant difference was found between NUDT15 C/T and its wild-type C/C (P = 0.004). There were only 3 patients with TPMT mutant genotype of A/G (1.4%) who participated in the research, and 1 of them was treated with AZA and developed leukopenia. The remaining 216 patients (98.6%) were found to bear the wild genotype of TPMT (A/A); among them, 79 patients received AZA, and 18 (22.8%) developed leukopenia, and there was no significant difference from those with A/G (P = 0.071). The frequency of TPMT mutation was 1.4%, and NUDT15 mutation rate was significantly higher and reached 20.1% (P = 0.000). Therefore, NUDT15 gene polymorphism was obviously a better biomarker than TPMT gene polymorphism in the prediction of AZA-induced leukopenia. CONCLUSION: Mutation rate of NUDT15 in Chinese IBD patients is higher than that of TPMT. NUDT15 polymorphism is a better predictor for AZA-induced leukopenia than TPMT polymorphism.
format Online
Article
Text
id pubmed-5829157
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-58291572018-02-28 Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease Wang, Hong-Hui He, Ying Wang, Hong-Xian Liao, Cheng-Ling Peng, Yu Tao, Li-Jian Zhang, Wei Yang, Hui-Xiang World J Gastroenterol Clinical Trials Study AIM: To observe gene polymorphisms of TPMT and NUDT15, and compare their predictive value for azathioprine (AZA)-induced leukopenia in inflammatory bowel disease (IBD). METHODS: This study enrolled 219 patients diagnosed with IBD in Xiangya Hospital, Central South University, Changsha, China from February 2016 to November 2017. Peripheral blood of all patients was collected to detect their genotypes of TPMT and NUDT15 by pyrosequencing at the Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Xiangya Hospital. Eighty patients were treated with AZA according to the disease condition. During the first month, patients who received AZA underwent routine blood tests and liver function tests once a week. The endpoint of the study was leukopenia induced by AZA. By analyzing patient characteristics, genotypes and leukopenia induced by drug use, we found the risk factors associated with AZA-induced leukopenia. RESULTS: There were 219 patients with IBD (160 men and 59 women), including 39 who were confirmed with ulcerative colitis (UC), 176 with Crohn’s disease (CD) and 4 with undetermined IBD (UIBD). There were 44 patients (20.1%) with mutant genotype of NUDT15 (C/T); among them, 16 received AZA, and 8 (50%) developed leukopenia. There were 175 patients (79.7%) with wild genotype of NUDT15 (C/C); among them, 64 received AZA, and 11 (17.2%) developed leukopenia. A significant difference was found between NUDT15 C/T and its wild-type C/C (P = 0.004). There were only 3 patients with TPMT mutant genotype of A/G (1.4%) who participated in the research, and 1 of them was treated with AZA and developed leukopenia. The remaining 216 patients (98.6%) were found to bear the wild genotype of TPMT (A/A); among them, 79 patients received AZA, and 18 (22.8%) developed leukopenia, and there was no significant difference from those with A/G (P = 0.071). The frequency of TPMT mutation was 1.4%, and NUDT15 mutation rate was significantly higher and reached 20.1% (P = 0.000). Therefore, NUDT15 gene polymorphism was obviously a better biomarker than TPMT gene polymorphism in the prediction of AZA-induced leukopenia. CONCLUSION: Mutation rate of NUDT15 in Chinese IBD patients is higher than that of TPMT. NUDT15 polymorphism is a better predictor for AZA-induced leukopenia than TPMT polymorphism. Baishideng Publishing Group Inc 2018-02-28 2018-02-28 /pmc/articles/PMC5829157/ /pubmed/29491687 http://dx.doi.org/10.3748/wjg.v24.i8.941 Text en ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Clinical Trials Study
Wang, Hong-Hui
He, Ying
Wang, Hong-Xian
Liao, Cheng-Ling
Peng, Yu
Tao, Li-Jian
Zhang, Wei
Yang, Hui-Xiang
Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease
title Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease
title_full Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease
title_fullStr Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease
title_full_unstemmed Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease
title_short Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease
title_sort comparison of tpmt and nudt15 polymorphisms in chinese patients with inflammatory bowel disease
topic Clinical Trials Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829157/
https://www.ncbi.nlm.nih.gov/pubmed/29491687
http://dx.doi.org/10.3748/wjg.v24.i8.941
work_keys_str_mv AT wanghonghui comparisonoftpmtandnudt15polymorphismsinchinesepatientswithinflammatoryboweldisease
AT heying comparisonoftpmtandnudt15polymorphismsinchinesepatientswithinflammatoryboweldisease
AT wanghongxian comparisonoftpmtandnudt15polymorphismsinchinesepatientswithinflammatoryboweldisease
AT liaochengling comparisonoftpmtandnudt15polymorphismsinchinesepatientswithinflammatoryboweldisease
AT pengyu comparisonoftpmtandnudt15polymorphismsinchinesepatientswithinflammatoryboweldisease
AT taolijian comparisonoftpmtandnudt15polymorphismsinchinesepatientswithinflammatoryboweldisease
AT zhangwei comparisonoftpmtandnudt15polymorphismsinchinesepatientswithinflammatoryboweldisease
AT yanghuixiang comparisonoftpmtandnudt15polymorphismsinchinesepatientswithinflammatoryboweldisease